SCHEMBL13645756

SCHEMBL13645756

CCCC(NC(C)=O)C(=O)NC(C)C(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC2 Q13490 3/20 0.47
REN P00797 1/20 0.40
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
TSHR P16473 2/20 0.39
SIRT6 Q8N6T7 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13645737 0.86 BIRC2 (0.42) BIRC2KMT2AMEN1TSHRALDH1A1
SCHEMBL711890 0.82 TAS1R3 (0.46) SIRT6SIRT1TAS1R3TAS1R1ALDH1A1
SCHEMBL3241409 0.82 TAS1R3 (0.46) SIRT6SIRT1TAS1R3TAS1R1ALDH1A1
SCHEMBL18950367 0.81 MAPT (0.52) BIRC2KMT2AMEN1TSHRALDH1A1
SCHEMBL21737912 0.80 BIRC2 (0.40) BIRC2KMT2AMEN1TSHRALDH1A1
SCHEMBL8372311 0.79 BIRC2 (0.59) BIRC2KMT2AMEN1TSHRALDH1A1
SCHEMBL8372310 0.79 BIRC2 (0.59) BIRC2KMT2AMEN1TSHRALDH1A1
SCHEMBL13645819 0.76 CA14 (0.43) BIRC2KMT2AMEN1TSHRALDH1A1
SCHEMBL21738188 0.76 CA14 (0.43) BIRC2KMT2AMEN1TSHRALDH1A1
SCHEMBL7776379 0.76 CA14 (0.43) BIRC2KMT2AMEN1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598244-B2 [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-7598244-B2 [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-01-11 US disclosed
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof HLA-C, TPMT, TAP1 BIRC2 2808/4885REN 1666/4885KMT2A 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.